Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza

Clinical Infectious Diseases

Volumn 63, Issue 3, 2016, Pages 330-337

  Kashiwagi, Seizaburo ^a   Watanabe, Akira ^b   Ikematsu, Hideyuki ^a   Uemori, Mitsutoshi ^c   Awamura, Shinichiro ^d   Ishida, Katsuyasu ^d   Nishioka, Satoshi ^d   Isobe, Koji ^d   Sumitani, Tokuhito ^d   Yamaguchi, Toshiko ^e   Igarashi, Yutaka ^e   Sato, Hideki ^e   Saito, Kouta ^e   Shibuya, Tomoyuki ^e   Enomoto, Shinya ^e   Oshika, Eiki ^e   Murakawa, Yasuko ^e   Kuroki, Haruo ^e   Maehara, Koji ^e   Miyazono, Yuko ^e   Umezawa, Yoshihiro ^e   Ono, Ryuta ^e   Saito, Kenji ^e   Takei, Jiro ^e   Takano, Mikiko ^e   Amemiya, Hideki ^e   Arakawa, Kazuo ^e   Matsubara, Shigenori ^e   Sugimoto, Kazumasa ^e   Kikumori, Hiroshi ^e   Sunami, Toshihiko ^e   Yoshimura, Ryota ^e   Takahashi, Toshikazu ^e   Nakamura, Yutaka ^e   Tsuboi, Keiichi ^e   Shinohara, Hidehisa ^e   Onari, Shigeru ^e   Tanabe, Michiko ^e   Taniguchi, Hiroshi ^e   Kihara, Mikio ^e   Yoshimitsu, Tatsuo ^e   Yokoyama, Takato ^e   Takasaki, Yoshio ^e   Yamashita, Yuji ^e   Harada, Hiroshi ^e   Aida, Katsumaro ^e   Shindo, Shizuo ^e   Shimomura, Kunihisa ^e   Kiyomatsu, Yumi ^e   Umezu, Toru ^e   Ikeda, Motohisa ^e   Iwaya, Minako ^e   Higashikawa, Masaki ^e   Inamitsu, Takeshi ^e   Tokunaga, Yasuyuki ^e   Okazaki, Satoru ^e   Tokunaga, Yoichi ^e   Maeda, Tetsunari ^e   Tahara, Hirofumi ^e   more..

^a Japan Physician's Association   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c Biostatistics and Data Management Department   (Japan)

^d DAIICHI SANKYO CO   (Japan)

^e NONE

Author keywords

influenza; laninamivir; neuraminidase inhibitor; post exposure; prophylaxis

Indexed keywords

LANINAMIVIR OCTANOATE; PLACEBO; ANTIVIRUS AGENT; ENZYME INHIBITOR; LANINAMIVIR; SIALIDASE; ZANAMIVIR;

ADULT; AXILLA TEMPERATURE; BRONCHOSPASM; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INCIDENCE; INFLUENZA; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FAMILY SIZE; INHALATIONAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FAMILY CHARACTERISTICS; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEURAMINIDASE; POST-EXPOSURE PROPHYLAXIS; YOUNG ADULT; ZANAMIVIR;

EID: 84981287575     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw255     Document Type: Review

References (22)

1. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003-32.
2. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.
3. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010; 51:1167-75.
4. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010; 54:2575-82.
5. Watanabe A. A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. J Infect Chemother 2013; 19:89-97.
6. Ikematsu H, Kawai N, Iwaki N, Kashiwagi S. The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season. J Infect Chemother 2014; 20:81-5.
7. Ikematsu H, Kawai N, Iwaki N, Kashiwagi S. Continued effectiveness of laninamivir octanate hydrate for influenza treatment in Japan: comparison between the 2011-2012 and 2012-2013 influenza seasons. J Infect Chemother 2014; 20: 799-803.
8. Ikematsu H, Kawai N, Iwaki N, Kashiwagi S. Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season. J Infect Chemother 2015; 21:802-7.
9. Kashiwagi S, Watanabe A, Ikematsu H, et al. Laninamivir octanoate for postexposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial. J Infect Chemother 2013; 19:740-9.
10. Kashiwagi S. Review of laninamivir octanoate for the postexposure prophylaxis against influenza. Jpn J Chemother 2013; 61:492-503.
11. Ishizuka H, Toyama K, Yoshiba S, Okabe H, Furuie H. Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers. Antimicrob Agents Chemother 2012; 56:3873-8.
12. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline: Guideline for Good Clinical Practice, June 1996. Available at: http:// www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/ E6-R1-Guideline.pdf. Accessed 23 January 2016.
13. National Institute of Infectious Diseases. Byogenkin kensyutsu manyual, 2003. Available at: http://www0.nih.go.jp/niid/reference/pathogen-manual-60.pdf. Accessed 7 September 2015. Japanese.
14. World Health Organization. CDC protocol of real-time RTPCR for influenza A (H1N1). 30 April 2009. Available at: http://www.who.int/csr/resources/publications/ swineflu/realtimeptpcr/en/index.html. Accessed 10 September 2015.
15. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285:748-54.
16. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting antiinfluenza virus activity. Antimicrob Agents Chemother 2009; 53:186-92.
17. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swineorigin H1N1 influenza viruses. Nature 2009; 460:1021-5.
18. Food and Drug Administration. Guidance for Industry Influenza: Developing Drugs for Treatment and/or Prophylaxis, 2011. Available at: http://www.fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm091219.pdf. Accessed 24 January 2016.
19. Ikematsu H, Kawai N, Iwaki N, Kashiwagi S. In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan. J Infect Chemother 2012; 18:529-33.
20. Ikematsu H, Kawai N, Iwaki N, Kashiwagi S. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan. J Infect Chemother 2014; 20:77-80.
21. Ikematsu H, Kawai N, Iwaki N, Kashiwagi S. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season. J Infect Chemother 2015; 21:39-42.
22. Ikematsu H, Kawai N, Iwaki N, Kashiwagi S. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus circulating in the Japanese 2013-2014 season. J Infect Chemother 2015; 21:634-8.